The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype

European Respiratory Review

Volumn 27, Issue 150, 2018, Pages

  Olson, Amy L ^a   Gifford, Alex H ^b   Inase, Naohiko ^c   Fernández Pérez, Evans R ^a   Suda, Takafumi ^d  

^a DEPARTMENT OF MEDICINE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGIC PNEUMONITIS; ASBESTOSIS; AUSTRALIA; CHINA; DEMOGRAPHY; DENMARK; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; ETHNICITY; FIBROSING ALVEOLITIS; GENETIC ASSOCIATION; GEOGRAPHIC DISTRIBUTION; HEALTH INSURANCE; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; JAPAN; LUNG BIOPSY; LUNG PARENCHYMA; LUNG SARCOIDOSIS; OCCUPATIONAL EXPOSURE; PHENOTYPE; POPULATION DYNAMICS; PREVALENCE; REVIEW; SEX DIFFERENCE; SILICOSIS; SOUTH KOREA; SPAIN; TAIWAN; UNITED STATES; ADULT; AGE; AGED; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; ENVIRONMENT; FEMALE; GENETIC PREDISPOSITION; LUNG; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; ENVIRONMENT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PHENOTYPE; PREVALENCE; PROGNOSIS; RISK FACTORS;

EID: 85058909703     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0077-2018     Document Type: Review

References (89)

1. Raghu G. Interstitial lung disease. In: Goldman L, Schafer A. Goldman’s Cecil Medicine. 25th Edn. Philadelphia, Saunders, 2016; pp. 575–588.
2. Flaherty KR, Brown KK, Wells AU, et al. Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res 2017; 4: e000212.
3. Wells AU, Brown KK, Flaherty KR, et al. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018; 51: 1800692.
4. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
5. Cottin V, Hirani NA, Hotchkin DL, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018; 27: 180076.
6. British Lung Foundation. Idiopathic pulmonary fibrosis. 2016. https://www.blf.org.uk/sites/default/files/4.% 20IPFpdf Date last updated: September 2016. Date last accessed: January 2018.
7. Maher T, Strongman H, Boggon R, et al. Idiopathic pulmonary fibrosis survival has not improved in the 21st century; analysis of CPRD gold primary care data. Thorax 2013; 68: A82–AA3.
8. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax 2011; 66: 462–467.
9. Kornum JB, Christensen S, Grijota M, et al. The incidence of interstitial lung disease 1995-2005: a Danish nationwide population-based study. BMC Pulm Med 2008; 8: 24.
10. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980–985.
11. Ley B, Urbania T, Husson G, et al. Code-based diagnostic algorithms for idiopathic pulmonary fibrosis. Case validation and improvement. Ann Am Thorac Soc 2017; 14: 880–887.
12. Esposito DB, Lanes S, Donneyong M, et al. Idiopathic pulmonary fibrosis in United States automated claims. Incidence, prevalence, and algorithm validation. Am J Respir Crit Care Med 2015; 192: 1200–1207.
13. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir Med 2014; 2: 566–572.
14. Fernández Pérez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010; 137: 129–137.
15. Ehrlich SF, Quesenberry CP Jr, Van Den Eeden SK, et al. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care 2010; 33: 55–60.
16. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810–816.
17. Rufino RL, Costa CHD, Accar J, et al. Incidence and mortality of interstitial pulmonary fibrosis in Brazil. Am J Respir Crit Care Med 2013: A1458.
18. Han S, Mok Y, Jee SH, et al. Incidence and mortality of idiopathic pulmonary fibrosis In South Korea. Am J Respir Crit Care Med 2013; 187: A1460.
19. Lai CC, Wang CY, Lu HM, et al. Idiopathic pulmonary fibrosis in Taiwan – a population-based study. Respir Med 2012; 106: 1566–1574.
20. Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 2014; 190: 773–779.
21. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165: 277–304.
22. Saad N, Camus P, Suissa S, et al. Statins and the risk of interstitial lung disease: a cohort study. Thorax 2013; 68: 361–364.
23. Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 2015; 46: 795–806.
24. Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, et al. Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J 2017; 50: 1602419.
25. Richeldi L, Rubin AS, Avdeev S, et al. Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Med 2015; 13: 237.
26. Hopkins RB, Burke N, Fell C, et al. Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada. Eur Respir J 2016; 48: 187–195.
27. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet 2017; 389: 1941–1952.
28. Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007; 104: 7552–7557.
29. Harari S, Madotto F, Caminati A, et al. Epidemiology of idiopathic pulmonary fibrosis in Northern Italy. PLOS ONE 2016; 11: e0147072.
30. Talbert J, Scwartz D. Pulmonary Fibrosis, Familial. Seattle, University of Washington, 2005.
31. Lee HL, Ryu JH, Wittmer MH, et al. Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest 2005; 127: 2034–2041.
32. Travis WD, Hunninghake G, King TE Jr, et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med 2008; 177: 1338–1347.
33. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733–748.
34. Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev 2015; 24: 102–114.
35. Belloli EA, Beckford R, Hadley R, et al. Idiopathic non-specific interstitial pneumonia. Respirology 2016; 21: 259–268.
36. Hyldgaard C, Hilberg O, Muller A, et al. A cohort study of interstitial lung diseases in central Denmark. Respir Med 2014; 108: 793–799.
37. Bendstrup E, Maher TM, Manali ED, et al. Challenges in the classification of fibrotic ILD. Sarcoidosis Vasc Diffuse Lung Dis 2015; 32: Suppl. 1, 4–9.
38. Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J 2013; 42: 750–757.
39. Skolnik K, Ryerson CJ. Unclassifiable interstitial lung disease: a review. Respirology 2016; 21: 51–56.
40. Olson AL, Brown KK, Fischer A. Connective tissue disease-associated lung disease. Immunol Allergy Clin North Am 2012; 32: 513–536.
41. Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ 2016; 352: h6819.
42. Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46: 976–987.
43. Cottin V. Idiopathic interstitial pneumonias with connective tissue diseases features: a review. Respirology 2016; 21: 245–258.
44. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569–2581.
45. Iqbal K, Kelly C. Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Ther Adv Musculoskelet Dis 2015; 7: 247–267.
46. Olson AL, Swigris JJ, Sprunger DB, et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011; 183: 372–378.
47. Bongartz T, Nannini C, Medina-Velasquez YF, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010; 62: 1583–1591.
48. Kelly CA, Saravanan V, Nisar M, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics – a large multicentre UK study. Rheumatology (Oxford) 2014; 53: 1676–1682.
49. Shaw M, Collins BF, Ho LA, et al. Rheumatoid arthritis-associated lung disease. Eur Respir Rev 2015; 24: 1–16.
50. Zeng X-F, Zhu S-I, Tan A-C, et al. Disease burden and quality of life of rheumatoid arthritis in China: a systematic review. Chin J Evid Based Med 2013; 13: 300–307.
51. Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc 2007; 4: 443–448.
52. Song JW, Lee HK, Lee CK, et al. Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30: 103–112.
53. Assayag D, Lee JS, King TE Jr. Rheumatoid arthritis associated interstitial lung disease: a review. Medicina (B Aires) 2014; 74: 158–165.
54. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest 2005; 127: 2019–2027.
55. Varga J. Systemic sclerosis (scleroderma). In: Goldman L, Schafer AL, eds. Goldman-Cecil Medicine. 25th Edn. Philadelphia, Saunders, 2016; pp. 1777–1784.
56. Cappelli S, Bellando Randone S, Camiciottoli G, et al. Interstitial lung disease in systemic sclerosis: where do we stand? Eur Respir Rev 2015; 24: 411–419.
57. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248–1254.
58. Volkmann ER, Tashkin DP. Treatment of systemic sclerosis-related interstitial lung disease: a review of existing and emerging therapies. Ann Am Thorac Soc 2016; 13: 2045–2056.
59. Schoenfeld SR, Castelino FV. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2015; 41: 237–248.
60. Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2007; 66: 754–763.
61. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003; 29: 239–254.
62. Chifflot H, Fautrel B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008; 37: 223–235.
63. Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers. Curr Opin Rheumatol 2012; 24: 165–170.
64. Kuo CF, See LC, Yu KH, et al. Epidemiology and mortality of systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol 2011; 40: 373–378.
65. Fernandez Perez ER, Swigris JJ, Forssen AV, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest 2013; 144: 1644–1651.
66. Barber C, Wiggans R, Carder M, et al. Epidemiology of occupational hypersensitivity pneumonitis; reports from the SWORD scheme in the UK from 1996 to 2015. Occup Environ Med 2017; 74: 528–530.
67. Morell F, Villar A, Montero MA, et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 2013; 1: 685–694.
68. Thomeer MJ, Costabe U, Rizzato G, et al. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J 2001; 18: Suppl. 32, 114s–118s.
69. Bang KM, Weissman DN, Pinheiro GA, et al. Twenty-three years of hypersensitivity pneumonitis mortality surveillance in the United States. Am J Ind Med 2006; 49: 997–1004.
70. Okamoto T, Miyazaki Y, Ogura T, et al. Nationwide epidemiological survey of chronic hypersensitivity pneumonitis in Japan. Respir Investig 2013; 51: 191–199.
71. Fernandez Perez ER, Kong AM, Raimundo K, et al. Epidemiology of hypersensitivity pneumonitis among an insured population in the United States: a claims-based cohort analysis. Ann Am Thorac Soc 2018; 15: 460–469.
72. Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lancet 2014; 383: 1155–1167.
73. Patterson KC, Strek ME. Pulmonary fibrosis in sarcoidosis. Clinical features and outcomes. Ann Am Thorac Soc 2013; 10: 362–370.
74. Arkema EV, Grunewald J, Kullberg S, et al. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J 2016; 48: 1690–1699.
75. Baughman RP, Field S, Costabel U, et al. Sarcoidosis in America. Analysis based on health care use. Ann Am Thorac Soc 2016; 13: 1244–1252.
76. Morimoto T, Azuma A, Abe S, et al. Epidemiology of sarcoidosis in Japan. Eur Respir J 2008; 31: 372–379.
77. Cowie R, Becklake M. Pneumoconioses. In: Murray & Nadel’s Textbook of Respiratory Medicine. 6th Edn. Philadelphia, Elsevier, 2016; pp. 1307–1330.
78. Soeberg M, Vallance DA, Keena V, et al. Australia’s ongoing legacy of asbestos: Significant challenges remain even after the complete banning of asbestos almost fifteen years ago. Int J Environ Res Public Health 2018; 15: 384.
79. Carder M, Darnton A, Gittins M, et al. Chest physician-reported, work-related, long-latency respiratory disease in Great Britain. Eur Respir J 2017; 50: 1700961.
80. Beckett W. Adverse effects of crystalline silica exposure. American Thoracic Society Committee of the Scientific Assembly on Environmental and Occupational Health. Am J Respir Crit Care Med 1997; 155: 761–768.
81. Leung CC, Yu IT, Chen W. Silicosis. Lancet 2012; 379: 2008–2018.
82. Health and Safety Executive (HSE) UK. Silicosis and coal workers’ pneumoconiosis. 2018. www.hse.gov.uk/ statistics/causdis/pneumoconiosis-and-silicosis.pdf. Date last updated: October 2018. Date last accessed: December 2018.
83. Bang KM, Mazurek JM, Wood JM, et al. Silicosis mortality trends and new exposures to respirable crystalline silica – United States, 2001–2010. MMWR Morb Mortal Wkly Rep 2015; 64: 117–120.
84. Bakhsh K, Ahmad N, Tabasum S, et al. Health hazards and adoption of personal protective equipment during cotton harvesting in Pakistan. Sci Total Environ 2017; 598: 1058–1064.
85. Blanco-Munoz J, Lacasana M. Practices in pesticide handling and the use of personal protective equipment in Mexican agricultural workers. J Agromedicine 2011; 16: 117–126.
86. Izudi J, Ninsiima V, Alege JB. Use of personal protective equipment among building construction workers in Kampala, Uganda. J Environ Public Health 2017; 2017: 7930589.
87. Nelson G. Occupational respiratory diseases in the South African mining industry. Glob Health Action 2013; 6: 19520.
88. The World Bank. Benefits and costs of reducing tuberculosis among Southern Africa’s mineworkers – overview. 2014. Washington, DC, World Bank Group, 2014. http://pubdocs.worldbank.org/en/770861483124917730/World-Bank-economic-analysis-on-addressing-TB-in-the-mines-brief.pdf. Date last updated: March 2014. Date last accessed: December 2018.
89. Tse LA, Dai J, Chen M, et al. Prediction models and risk assessment for silicosis using a retrospective cohort study among workers exposed to silica in China. Sci Rep 2015; 5: 11059.